ENDV Stock Analysis
EN
Uncovered
Endonovo Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Endonovo Therapeutics, Inc. is a biotechnology company engaged in the development of a bio-electronic approach to regenerative medicine. The company is headquartered in Woodland Hills, California. The company went IPO on 2012-03-09. The firm is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The firm's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, using pulsed short-wave radiofrequency at 27.12 megahertz (MHz) is used for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The company offers an alternative, non-opioid treatment through its Electroceuticals systems.